Grail Inc
GRAL
NASDAQ
Biotechnology
$67.87
USD
-0.37 (-0.54%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.05B
Volume 433.0K
Revenue
$165.26M
TTM
+23.1%
YoY
Gross Margin
50%
TTM
+15.1%
YoY
Net Income
$-391.59M
TTM
+11.6%
YoY
Operating Cash Flow
$-294.75M
TTM
+20.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 35.5 | 36.2 | 43.6 | 40.8 | 44.7 |
YoY Growth | +11.2% | +26.3% | +14.0% | +28.1% | +25.7% |
Cost of Revenue | 53.3 | 49.9 | -79.2 | 55.1 | 57.3 |
Gross Profit | -17.8 | -13.7 | 122.8 | -14.3 | -12.6 |
Selling, General & Administrative | 66.5 | 62.9 | 66.4 | 73.4 | 88.4 |
Other Operating Expenses | 28.0 | 0.0 | 0.0 | 0.0 | 25.4 |
Total Operating Expenses | 141.1 | 111.6 | 247.2 | 121.5 | 161.2 |
Operating Income | -158.9 | -125.3 | -124.4 | -135.8 | -173.8 |
EBITDA | -91.7 | -86.3 | -85.5 | -97.0 | -109.7 |
Other Income / Expense | -0.8 | 0.5 | -0.1 | 0.3 | -0.2 |
Total Other Income / Expense | 6.0 | 6.6 | 7.9 | 8.2 | 7.1 |
Income Before Income Taxes | -152.9 | -118.7 | -116.5 | -127.5 | -166.7 |
Income Taxes | -38.9 | -29.7 | -17.3 | -34.3 | -56.5 |
Net Income | -114.0 | -89.0 | -99.2 | -93.2 | -110.2 |
Consolidated Net Income / Loss | -114.0 | -89.0 | -99.2 | -93.2 | -110.2 |
Net Income Attributable to Common Shareholders | -114.0 | -89.0 | -99.2 | -93.2 | -110.2 |
Basic EPS | -$3.18 | -$2.46 | -$2.43 | -$2.29 | -$2.56 |
Diluted EPS | -$3.18 | -$2.46 | -$2.43 | -$2.29 | -$2.56 |
Basic Shares Outstanding | 35.8M | 36.1M | 40.8M | 40.6M | 43.1M |
Diluted Shares Outstanding | 35.8M | 36.1M | 40.8M | 40.6M | 43.1M |